BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

The lupus community gets its first break in a long while with three products showing efficacy in late-stage trials for systemic lupus erythematosis. That is welcome news in a disease that saw seven compounds fail...
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

A trio of companies reported positive data from late-stage systemic lupus erythematosis trials, raising hopes that new treatments are on the horizon for an indication that has seen only one new therapy approved in the...
BioCentury | Aug 29, 2019
Clinical News

New lupus endpoint key to Phase III success for AZ’s anifrolumab

AstraZeneca's positive data for anifrolumab is the first successful Phase III trial in lupus in about a decade. But a previous Phase III failure for the mAb on a different endpoint leaves the pharma unable...
BioCentury | Aug 20, 2019
Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

Juvenescence closes $100M series B Juvenescence Ltd. (Douglas, Isle of Man) said it has closed its $100 million series B round and reiterated plans to seek an IPO. Investors included the company's founders plus Grok...
BioCentury | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BioCentury | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

Lloyd Sanders will succeed Murali Prahalad as president and CEO of cancer diagnostic company Epic Sciences Inc. (San Diego, Calif.). Sanders was president of the oncology segment of molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN)....
BioCentury | Feb 8, 2019

Extending a Bold vision for Longevity

After making a handful of longevity-related investments as a partner at Bold Capital, Sergey Young is seeking to invest about $100 million via the Longevity Vision Fund, a new vehicle dedicated solely to the field...
BioCentury | Feb 8, 2019
Company News

Juvenescence, Buck Institute launch company to research ketones for age-related diseases

Juvenescence Ltd. (Douglas, Isle of Man) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form BHB Therapeutics Ltd. The new company will focus on novel approaches to inducing a state of...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
Items per page:
1 - 10 of 127